For instance, the carcinoembryonic antigen (CEA) in colorectal cancer patients [37] and prostate-specific membrane antigen (PSMA) in patients with metastatic cancers [38], respectively, demonstrated good safety profiles although the immunogenicity responses have been modest. This evidence concerns the gene FOLH1 and colorectal cancer.